research research research-lab cancer-center C true

Cellular Immunotherapy Program

The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells.
Cellular Immunotherapy lab.
Cellular Immunotherapy lab.

Contact Information

Cellular Immunotherapy Program

Email: MGHCIP@mgh.harvard.edu

Support the Cellular Immunotherapy Program

Your support can help advance the research and development of promising cellular therapies that can harness the immune system to fight cancer. Make gift.

Explore the Cellular Immunotherapy Program

    Overview

    The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.

    Our objectives:

    We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.

    • Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
    • Enable translational research and collaboration
    • Optimize immune monitoring and laboratory correlatives of clinical observations
    • Promote cellular therapy education through education sessions
    • Provide high quality care and management of patients receiving cellular therapies
    • Obtain and maintain FACT accreditation for the administration of immune effector cells
    • Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies

    Clinical Trials

    View Cellular Therapy clinical trials.

    CAR T-Cell Therapies

    The Mass General Cancer is an authorized treatment center for two FDA approved CAR T-cell therapies for adult patients with lymphoma, Yescarta and Kymriah. Learn more.

    Videos

    Of the many different approaches to activate the body’s immune system against cancer, CAR T-cell therapy is one of the most high tech and powerful treatments.

    Marcela V. Maus, MD, PhD, Director of the Cellular Immunotherapy Program at the Mass General Cancer Center, was awarded a 2017 Stand Up to Cancer Innovative Research Grant for her work on "Potentiating Novel Engineered Cellular Therapies for Solid Tumors."

    Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.

    Kiss 108 FM’s Billy Costa gets a doctor’s perspective of CAR T-cell therapy with Mass General Cancer Center’s clinical director for the Center of Lymphoma, Dr. Jeremy Abramson.

    Kiss 108 FM’s Billy Costa sits down with Dr. Marcela Maus, director of cellular immunotherapy at the Mass General Cancer Center, and discusses what CAR T-cell therapy is, who is eligible for treatments, and the future direction of CAR T-cell therapy.

    Kiss 108 FM’s Billy Costa discusses CAR T-cell therapy with Mass General Cancer Center’s Dr. Matthew Frigault, medical oncologist and administrative director for Cellular Therapy Services, who explains how this therapy has the potential to impact patients in immense ways.

    Watch how Mass General patient Jenn Gilmann has already benefited from immunotherapy.

    1 of 7

    Resources

    Clinical Trials

    Clinical Trials

    View Cellular Therapy clinical trials.

    CAR T-Cell Therapies

    CAR T-Cell Therapies

    View CAR T-Cell Therapies.

    Publications

    Publications

    View publications by Marcela Maus, MD, PhD on PubMed.

    FACT Standards

    FACT Standards

    FACT Standards for Immune Effector Cells.

    FACT information

    FACT information

    The why, what, and how of the new FACT standards for immune effector cells.

    Maus Lab

    Maus Lab

    Learn about the Maus laboratory.

    Immune Monitoring Lab

    Immune Monitoring Lab

    Learn about the Immune Monitoring laboratory.

    Cellular Therapy & Transplantation Lab

    Cellular Therapy & Transplantation Lab

    Learn about the Cellular Therapy & Transplantation Laboratory.

    Blood Transfusion Service

    Blood Transfusion Service

    Learn about Mass General's Blood Transfusion Service.

    Honors & Awards

    View Cellular Immunotherapy Program team members honored for their commitment to the fight against cancer.

    Marcela V. Maus, MD, PhD

    As the director of the Cellular Immunotherapy Program at the Mass General Cancer Center, Marcela Maus, MD, PhD, is following a childhood dream of fixing genes gone wrong in the pursuit of a cure for cancer.

    Read more
    Marcela Maus

    Cellular Therapy and Transplantation Laboratory

    The CTTL team plays an integral part in stem cell processing, transplant infusions and bone marrow harvests. Technologists also participate in numerous immunotherapy clinical trials to aid in the progression of research and improve patients’ lives.

    Read more
    Cellular Therapy and Transplantation Laboratory team.
    1 of 2

    Featured Articles

     

    >3,300 People
    participated in Clinical Trials at the Mass General Cancer Center last year

    This helped lead to new knowledge and breakthrough therapies.

    Learn more
    Center for Cancer Research

    The scientific engine for discovery for the Mass General Cancer Center.

    Learn more

    Contact the Cancer Center

    Contact the Mass General Cancer Center to make an appointment or learn more about our programs.

    Request an appointmentClinical trials and research617-726-5130